Related Experiment Video
Updated: May 18, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Reboxetine in clinical practice: a review
1Department of Neuroscience and Imaging, "G. D'Annunzio" University of Chieti, Italy. g.sepede@unich.it
La Clinica Terapeutica
|September 26, 2012
Summary
Reboxetine, a selective noradrenaline reuptake inhibitor (NaRI), shows varied efficacy in treating depression and other conditions. This review compares its risks and benefits for clinical use.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI) and the first in its antidepressant class.
- Approved in Europe for Major Depression, its US application was rejected.
- Investigated for Narcolepsy, ADHD, Panic Attack Disorder, Parkinson's-related depression, and Cocaine Dependence Disorder.
Purpose of the Study:
- To review and discuss recent literature on reboxetine.
- To compare the risks and benefits of reboxetine in clinical practice.
Main Methods:
- Literature review of studies on reboxetine's efficacy and safety.
- Comparative analysis of reboxetine against other antidepressants and placebo.
- Assessment of reboxetine's utility in various neurological and psychiatric conditions.
Main Results:
- Reboxetine has demonstrated comparable efficacy to other antidepressants in treating major depressive illness.
- Recent reports challenge its effectiveness and safety for acute depression.
- Evidence suggests potential benefits in conditions beyond major depression.
Conclusions:
- Reboxetine's clinical utility requires careful consideration of its risk-benefit profile.
- Further research is needed to clarify its role in acute depression treatment.
- Reboxetine remains a potential therapeutic option for specific patient populations and conditions.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications